The conversation discusses concerns about the effectiveness of RU58841 due to high temperatures during delivery. A user reassures that the heat will not affect its efficacy.
A user experienced severe scalp itching with MPB and found Nizoral ineffective. A doctor diagnosed seborrheic eczema and prescribed Betacap, which relieved the itching.
A user with diffuse hair loss for a decade tried various treatments, including LLLT Helmet, supplements, topicals, and hair transplants. They found relief from scalp inflammation and itching using a topical solution made from crushed Xeljanz pills mixed with ethyl alcohol.
Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.
TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.
The user experiences an itchy scalp and finds relief using shampoo and Zyrtec, which helps with inflammation. They are unsure if the issue is related to histamines or seborrheic dermatitis.
Microneedling can cause infections if not done carefully; users suggest using alcohol swabs and reducing needle depth to avoid issues. Proper sanitation and gentle pressure are key to preventing bleeding and infection.
A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.
Switching milk brands cleared scalp inflammation and other symptoms, but hair shedding continues. The user hopes shedding will stop as hair cycles progress.
RU58841 helped reduce scalp itching for some users within a week, while others experienced immediate relief. Some users reported initial irritation from the solution, possibly due to the carrier used.
Hair loss affects confidence, with discussions on treatments like finasteride, minoxidil, and RU58841. Emphasis is placed on self-acceptance and building confidence beyond appearance.
Setipiprant and Fevipiprant are questioned for their effectiveness in hair maintenance, with skepticism due to lack of convincing results beyond vellus hair growth. The user is satisfied with Minoxidil and Finasteride but is curious about the potential of DP2 inhibitors.
The conversation discusses alternatives for hair loss treatment for someone allergic to finasteride, suggesting options like hair systems, topical anti-androgens such as CB-03-01, RU58841, and kx-826. It highlights the challenges faced by individuals allergic to anti-androgen inhibitors and the need for more information on this topic.
The conversation discusses preventing infection from derma stamping for hair loss treatment, with suggestions to reduce needle depth and consider alternatives like tretinoin. The user experienced irritation possibly from zinc chloride and stopped using the shampoo and derma stamping.
The conversation discusses CRISPR-on & CRISPR-off as a potential cure for baldness, contrasting it with hair cloning and other treatments like Minoxidil, finasteride, and RU58841. It also mentions the potential of mRNA for gene expression control and the prioritization of gene editing for severe genetic conditions.
MCL-1 protein may help maintain hair follicles in the growth phase and prevent miniaturization. There is interest in experimental treatments like exosomes, peptides, or stem cell serums to upregulate MCL-1 for hair loss, especially for those not using minoxidil or finasteride.
Orient Bio is developing a PLGA formulated version of Cyclosporine A to stimulate hair growth without its immunosuppressant effects. Users discuss various treatments like Clascoterone, PP405, minoxidil, and tacrolimus, expressing hope for new developments and sharing personal experiences with these treatments.
Microneedling is discussed as a favorable hair loss treatment, with no consensus on whether to glide or remove the device between areas. Scalp irritation varies by individual, and some users report no need for gel during the process.
A Swiss product called Redensyl, which is supposed to target hair follicle stem cells and has recently been marketed in Europe. The post inquires if anyone has had any experience with the product.
Quitting RU58841 after over two years reduced scalp itching and inflammation, despite concerns about losing hair gains. The user continues using finasteride and oral minoxidil.
The conversation is about dealing with hair shedding due to seborrheic dermatitis and recent illness. Recommendations include treating seborrheic dermatitis with ketoconazole, correcting vitamin D deficiency, and improving sleep.
A user was prescribed betamethasone dipropionate spray for a receding hairline, which caused skin peeling and depigmentation. They stopped using it and are considering alternatives like BPC-157/TB-500 for healing.
The conversation discusses using NAC and quercetin as supplements for hair loss, with some users also mentioning finasteride. NAC is highlighted for its potential benefits, but concerns about its safety and absorption are also raised.
P5P supplementation helped reverse finasteride side effects, particularly by lowering prolactin levels and restoring sensitivity. The user experienced significant improvement within a day and full recovery in a few days.
A potential new hair loss treatment, HMI-115, and the possibility of discontinuing finasteride in favor of it. The conversation also includes discussion about other benefits of using finasteride.
Scientists discovered a new T cell treatment that could regrow hair. Users are skeptical but hopeful, with some relying on finasteride and minoxidil in the meantime.
A user's father experienced hair regrowth and other health improvements after two IV exosome treatments. The user also had four rounds of exosome therapy, noting significant hair regrowth and relief from headaches, but no change in gray hair.
HMI 115 is being discussed as a potential hair loss treatment, with skepticism due to past disappointments like cosmeRNA, brezula, and pyrilutamide. The user is questioning if they should be hopeful for new developments in the next six years.